ArticleHaematologica2018
Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.
Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Article
- Histiocytic sarcoma with a common clonal origin emerged after 33 years from B-cell precursor acute lymphoblastic leukemia.Journal of clinical and experimental hematopathology : JCEH · 2026Article
- Histiocytic Sarcoma: A Review and Update.International journal of molecular sciences · 2025Review
- Primary CNS histiocytic sarcoma: Two case reports highlighting a novel MIGA2::BRAF gene fusion and genome-wide DNA methylation profiling results.Journal of neuropathology and experimental neurology · 2024Article
- Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis.American journal of hematology · 2024Article
- Primary pulmonary histiocytic sarcoma with high PD-L1 expression benefited from immunotherapy: A case report and bioinformatic analysis.The clinical respiratory journal · 2024Article
- Multiple disciplinary team management of rare primary splenic malignancy: Two case reports.World journal of clinical cases · 2022Article
- A case of recurrent refractory cervical primary histiocytic sarcoma treated with pembrolizumab.International cancer conference journal · 2022Article
- Primary splenic histiocytic sarcoma successfully treated with splenectomy: a case report and literature review.International cancer conference journal · 2022Article
- An advanced case of gastric histiocytic sarcoma treated with chemotherapy and gastrectomy: a case report and review of literature.Clinical journal of gastroenterology · 2021Review
- Case Report: Long-Term Response to Radiotherapy Combined With Targeted Therapy in Histiocytic Sarcoma Harboring Mutations in MAPK and PI3K/AKT Pathways.Frontiers in oncology · 2021Article
- Activating Mutations inGenes · 2019Article
- Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- Rare myeloid sarcoma with KMT2A (MLL)-ELL fusion presenting as a vaginal wall mass.Diagnostic pathology · 2019Article
- A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.International journal of hematology · 2019Article
- Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma.Pediatric blood & cancer · 2019Article
- Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma".Haematologica · 2018Article
- Review
- PDL1 Expression and Outcomes in Histiocytic Neoplasms.Case reports in oncologyArticle
- Pembrolizumab Combined With GDP Regimen Inducing Sustained Remission in Histiocytic Sarcoma: A Case Report.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.